✦ LIBER ✦

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia

✍ Scribed by Visco, Carlo; Finotto, Silvia; Pomponi, Fabrizio; Sartori, Roberto; Laveder, Francesco; Trentin, Livio; Paolini, Rossella; Di Bona, Eros; Ruggeri, Marco; Rodeghiero, Francesco

Book ID: 120434446
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 98 KB
Volume: 88
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.23391

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in combination with high-dose

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

✍ Lukáš Smolej; Michael Doubek; Anna Panovská; Martin Šimkovič; Yvona Brychtová; D 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Bendamustine Combined With Rituximab in

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

✍ Fischer, K.; Cramer, P.; Busch, R.; Stilgenbauer, S.; Bahlo, J.; Schweighofer, C 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 141 KB

Rituximab in combination with high-dose

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

✍ Castro, J E; Sandoval-Sus, J D; Bole, J; Rassenti, L; Kipps, T J 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB

Early Results of a Phase II Study Adding

Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

✍ M.L. Sorror; B. Storer; B.M. Sandmaier; T. Chauncey; B. Bruno; N.N.S. Andersen; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 93 KB